IL2 and skin squamous cell carcinoma: It is arguable that given the biological propensity for cSCC to evade immune systems in the setting of iatrogenic immunosuppression, an IL-2 based intra-lesional immunotherapy treatment strategy should be first line consideration for all cSCC lesions.